1. Scrip
  2. >>Therapy Areas

Richard Kender joins Poxel's board of directors

 
• By Lucie Ellis-Taitt

Lyon, France-based Poxel, a biopharmaceutical company developing drugs to treat type 2 diabetes, has named Richard N Kender to its board of directors as an independent board member. Most recently Mr Kender was senior vice-president of business development and corporate licensing at Merck & Co.

Lyon, France-based Poxel, a biopharmaceutical company developing drugs to treat type 2 diabetes, has named Richard N Kender to its board of directors as an independent board member. Most recently Mr Kender was senior vice-president of business development and corporate licensing at Merck & Co.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.